ID: ALA2408069

Max Phase: Preclinical

Molecular Formula: C33H43N7O5

Molecular Weight: 617.75

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCN(CC)c1ncc(N(CC)C(=O)NCCc2ccccc2)c(N[C@@H](Cc2ccc(OC(=O)N3CCCC3)cc2)C(=O)O)n1

Standard InChI:  InChI=1S/C33H43N7O5/c1-4-38(5-2)31-35-23-28(40(6-3)32(43)34-19-18-24-12-8-7-9-13-24)29(37-31)36-27(30(41)42)22-25-14-16-26(17-15-25)45-33(44)39-20-10-11-21-39/h7-9,12-17,23,27H,4-6,10-11,18-22H2,1-3H3,(H,34,43)(H,41,42)(H,35,36,37)/t27-/m0/s1

Standard InChI Key:  AWGJFTQNOSRFEP-MHZLTWQESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 617.75

Molecular Weight (Monoisotopic): 617.3326

AlogP: 4.80

#Rotatable Bonds: 14

Polar Surface Area: 140.23

Molecular Species: ACID

HBA: 8

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 2.53

CX Basic pKa: 7.09

CX LogP: 3.11

CX LogD: 2.64

Aromatic Rings: 3

Heavy Atoms: 45

QED Weighted: 0.23

Np Likeness Score: -1.02

References

1. Xu YZ, Smith JL, Semko CM, Rossiter KI, Fukuda JY, Dappen MS, Quincy DA, Konradi AW, Mao W, Welch B, Dreyer ML, Samant B, Zhang H, Lugar J, Liao Z, Henschel C, Petersen E, Vandevert C, Shoemaker M, Wehner N, Mutter L, Shopp G, Krimm M, Chen L, Wipke B, Dofiles L, Gallager I, Sauer JM, Messersmith EK, Pleiss MA, Bard F, Yednock TA..  (2013)  Orally available and efficacious α4β1/α4β7 integrin inhibitors.,  23  (15): [PMID:23777782] [10.1016/j.bmcl.2013.05.076]

Source

Source(1):

• Scientific Literature